Immutep Ltd ( (AU:IMM) ) has shared an update.
Immutep Limited reported a 77% increase in total revenue and other income for the half-year ended 31 December 2024, amounting to A$7,276,004. Despite this growth, the company experienced a 5% rise in net loss after tax to A$22,377,429, primarily due to increased R&D and intellectual property expenses related to clinical trials and staff costs. However, the company benefited from a net gain on foreign exchange and increased interest and grant income, which partially offset the higher expenses. The report highlights Immutep’s continued investment in research and development, reflecting its strategic focus on advancing its clinical programs in the competitive biotechnology sector.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments for cancer and autoimmune diseases. The company is known for its innovative research in leveraging the LAG-3 immune control mechanism to develop novel therapies.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $281.6M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.